Oppenheimer Cuts argenx (ARGX) Price Target to $1,038

Oppenheimer has reaffirmed its Outperform rating for argenx SE, adjusting the price target to $1,038, a 24.95% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer cut its price target on argenx SE ($ARGX) to $1,038 from $1,100 on October 12, 2026, and rates the stock "Outperform".

Since the rating, $ARGX is up 0.8% to date (from the $812.30 close on Oct 12, 2026).

ARGX argenx SE

$819.14 -2.48% year to date

Daily close · Oct 16, 2026

Key Points

Oppenheimer reiterated its Outperform rating on argenx SE and lowered the price target from $1,100 to $1,038 on October 12, 2026.
Oppenheimer's $1,038 price target implies 24.95% upside from argenx SE's ($ARGX) current $830.71 share price.
The stock trades recently around $830.71, which is about 20% below Oppenheimer's new target price.
Analysts have mixed views, with Wedbush maintaining its Outperform rating at a $1,150 target, while Evercore ISI Group recently adjusted their target down to $1,078.

Get $ARGX trade alerts by text

We text you when insiders, Congress or big funds trade $ARGX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures

Oppenheimer has reiterated its Outperform rating on argenx SE (NasdaqGS: ARGX) and adjusted its price target from $1,100 to $1,038 on October 12, 2026. This target is 20% lower than the recent trading price of $830.71 as of October 16, 2026.

Oppenheimer's Call on argenx SE

Oppenheimer's updated price target reflects a shift in its outlook for argenx SE, a company focused on developing therapies for autoimmune diseases. The firm maintains a positive view, suggesting that the company’s future prospects remain strong despite the target adjustment.

Other Institutional Activity in argenx SE

Several other institutional investors have also made moves regarding argenx SE. FMR, LLC holds 5,231,452 shares, worth about $4.29 billion, having increased its position by 240,561 shares. Meanwhile, Jupiter Topco LLC saw a 100% increase, adding 1,237,008 shares for a total of 2,474,015 shares valued at approximately $2.03 billion. Conversely, Price (T.Rowe) Associates Inc reduced its stake by 696,933 shares, now holding 2,678,047 shares worth around $2.19 billion.

argenx SE Stock Down 16.1%

As of October 16, 2026, argenx SE shares are trading around $830.71, which is significantly below Oppenheimer's new price target of $1,038. This suggests that the stock may be undervalued based on the firm's outlook. The company has experienced strong revenue growth of 59.3% year-over-year, which could support future price movements.

12-month forecast

$ARGX price target

argenx SE daily closes and this analyst's $1,038 target. Not advice.

Recent Earnings

In its most recent earnings report, argenx SE posted a trailing twelve-month revenue of approximately $5.32 billion and earnings per share (EPS) of $26.22. The company is set to report its next earnings on October 22, 2026, which may provide additional insights into its financial health.

Insider Buying and Selling at argenx SE

This absence of insider activity might indicate a stable outlook from the company’s executives regarding its future performance.

Analysts Set New Price Targets

On October 12, 2026, Oppenheimer maintained its Outperform rating on argenx SE with a price target of $1,038. Earlier, on October 9, 2026, Evercore ISI Group adjusted their target down to $1,078 while keeping their Outperform rating, and Baird maintained a Neutral rating with a target of $823.

About argenx SE

argenx SE is a biopharmaceutical company based in Amsterdam, Netherlands, that develops therapies for autoimmune diseases. Its products, such as VYVGART, are used in the treatment of conditions like generalized Myasthenia Gravis (gMG). The recent analyst activity reflects ongoing interest in the company's innovative treatments and market potential.

Bottom Line

Investors should watch for argenx SE's upcoming earnings report on October 22, 2026, which could shed light on the company's performance and future guidance. Furthermore, with varying analyst targets, it will be interesting to see how the market reacts to these updates.